Tweets
Did you know? 🤔
Capillaroscopy is performed on the nailfold because it is the area where the capillaries are fully visualized compared to the skin where capillary tips are only seen.
This capillaroscopy session with Dr. Cutolo is so high yield I'd say! 🤓
@RheumNow #ACR24 https://t.co/8AN7RXUDrM
sheila @RHEUMarampa ( View Tweet )
3 months 3 weeks ago
#Poorer responses to #Rx in
#Females vs #males
Sex hormone and pathway differences
explained
👇
Biological differences
F start worse in disease activity
F May have ⬇️ response to #Rx
Yr in Preview C Ritchlin
@lihi_eder’s PsA work quoted
ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL
Janet Pope @Janetbirdope ( View Tweet )
3 months 3 weeks ago
VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA.
RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month:
88% (ELISA) vs. 75%
96% (OPA) vs. 88%
At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
3 months 3 weeks ago
Hydralazine - known culprit of drug-induced AAV
How does hydral (H) AAV differ from primary (1) AAV?
đź’Ą High dual positivity MPO/PR3
đź’Ą DAH / pleuritis more common in H-AAV
đź’Ą ENT, constitutional, nervous, ILD in 1-AAV
đź’Ą More 6mo remission in H-AAV
@rheumnow #ACR24 Abst 2496
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
3 months 3 weeks ago
Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr
Links:
Richard Conway @RichardPAConway ( View Tweet )
3 months 3 weeks ago
Severe thrombocytopenia (TP) is rare but linked to major organ involvement and poor prognosis in #SLE. Data from the RISE registry shows TP in 9.3% of SLE patients, with higher prevalence in males, African-Americans+ those with multiple comorbidities.
#ACR24 @RheumNow abst#2680
Bella Mehta @bella_mehta ( View Tweet )
3 months 3 weeks ago
In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity.
Mechanism? NAC reduces rapamycin (mTOR) activation.
Common AEs: nausea, vomiting
@RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP
Links:
sheila @RHEUMarampa ( View Tweet )
3 months 3 weeks ago
Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs
Links:
Richard Conway @RichardPAConway ( View Tweet )
3 months 3 weeks ago
In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II
#ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe
Jiha Lee @JihaRheum ( View Tweet )
3 months 3 weeks ago
Difficult to Manage Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24
https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
SELECT-GCA suggests JAKis may be the new kid on the block
Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select.
https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago